Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcuma, particularly Curcuma longa (turmeric), has been studied for its potential to support cancer patients, especially in reducing the side effects of conventional cancer treatments such as chemotherapy and radiotherapy. The primary active constituent, curcumin, exhibits anti-inflammatory, antioxidant, and immunomodulatory properties. Several preclinical and clinical studies have investigated curcumin's ability to alleviate treatment-related side effects, such as oral mucositis, radiation dermatitis, and chemotherapy-induced nausea. For example, small randomized controlled trials have reported benefits of topical curcumin for radiation-induced skin reactions and oral curcumin for reducing the severity of oral mucositis in patients undergoing radiotherapy or chemotherapy. However, results are mixed, and many studies are limited by small sample sizes, variability in dosing, and formulations with poor bioavailability. Systematic reviews generally conclude that curcumin is safe and may offer modest benefits in side effect management, but emphasize the need for larger, high-quality trials. Thus, while there is some scientific evidence supporting the use of Curcuma for reducing cancer treatment side effects, it is not robust or definitive enough for strong recommendations.

More about Curcuma
More about Cancer Treatment (reducing side effects)

Other ingredients used for Cancer Treatment (reducing side effects)

Other health conditions supported by Curcuma

Products containing Curcuma